The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies

Thu, 24th Sep 2020 18:12

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

----------

Carr's Group PLC - Carlisle, England-based agriculture machinery distributor and engineering firm - Names Hugh Pelham as new chief executive officer, succeeding Tim Davies. Pelham to join Carr's as CEO designate on January 4 and will succeed Davies on January 12 at conclusion of annual general meeting. "He is currently Global President at Minova, part of ASX-listed Orica, which is a manufacturer and supplier of chemical and mechanical earth control products, adhesives and support equipment. Minova has revenues of AUD600 million, generated from 40 countries globally," Carr's said.

----------

Renold PLC - Manchester-based supplier of industrial chains and related power transmission products - Notes Jim Haughey, named finance director back in May, will join from October 1. "Jim has extensive experience of listed companies with multinational and manufacturing operations, at FKI PLC, Bridon International Ltd, Cosalt PLC, Bodycote PLC and Mpac Group PLC and joins Renold from his latest appointment at Drive Devilbliss Healthcare Ltd," Renold said.

----------

Evgen Pharma PLC - Liverpool-headquartered clinical-stage drug development company - Names Huw Jones as CEO, taking over in "early October". "Jones has over 30 years' experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on pre-clinical and clinical drug development, dilutive and non-dilutive financing and business development. He is chair of Chronos Therapeutics Ltd, Non-Executive Director of Rexgenero Ltd and Strategic Advisor to Gen2 Neuroscience Ltd," Evgen said.

----------

Scancell Holdings PLC - cancer treatment firm - Names Susan Davies as non-executive director with immediate effect, with current Non-Executive Alan Lewis stepping down due to ill health.

----------

Secure Trust Bank PLC - UK retail and commercial bank - Says Chief Financial Officer Rachel Lawrence, who took over on September 7, was appointed as executive director on Wednesday.

----------

Eleco PLC - London-based construction software developer - Chair John Ketteley steps down with immediate effect. Deputy Serena Lang agrees to act as chair. Chief Operating Officer Jonathan Hunter named as interim CEO.

----------

Boku Inc - US-based mobile payments solution provider - Adds Charlotta Ginman to board as non-executive with immediate effect. Has held senior roles with UBS Group AG and Deutsche Bank AG.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Jun 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Feb 2020 16:17

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Read more
6 Feb 2020 13:45

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Read more
17 Dec 2019 15:35

Evgen Pharma narrows loss, foresees 'clinical success'

(Sharecast News) - Evgen Pharma on Tuesday reported a narrowed interim loss and said it was confident of clinical success as it continues to develop its SFX-01 treatment.

Read more
17 Dec 2019 11:28

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Read more
10 Dec 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
5 Dec 2019 16:36

Evgen Pharma to advance SFX-01 trial with University of Dundee

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has entered into a memorandum of understanding with the University of Dundee, it announced on Thursday, to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Read more
5 Dec 2019 15:19

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Read more
11 Nov 2019 12:23

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

Read more
11 Nov 2019 10:22

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

Read more
11 Nov 2019 09:11

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Read more
23 Sep 2019 13:09

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Read more
23 Sep 2019 10:03

Evgen Pharma upbeat on latest news from SFX-01 studies

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Monday that five patients who participated in the 'STEM' trial received 'SFX-01' treatment for more than one year, with two of those patients continuing to be treated with SFX-01.

Read more
28 Aug 2019 14:30

Evgen Pharma completes patient study visits in 'SAS' phase 2 trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered in the double-blind, placebo-controlled 'SAS' phase 2 clinical trial has taken place.

Read more
28 Aug 2019 12:06

Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial

(Alliance News) - Evgen Pharma PLC said Wednesday it has entered its last patient in the double-blind, placebo-controlled SAS Phase II clinical trial that is testing its SFX-01 product, aimed at a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.